Marina Protopopova, Elena Bogatcheva, Boris Nikonenko, Sam Hundert, Leo Einck and Carol A. Nacy Pages 301 - 316 ( 16 )
The last 10 years have seen resurgent industry activity in discovery and development of new drugs for the treatment of tuberculosis (TB), a growing widespread and devastating (more than 2 million deaths annually) bacterial infection that is of increasing concern in developing and developed nations alike. This review describes drugs currently being evaluated in the clinic for treatment of uncomplicated and drug resistant pulmonary TB, and updates the literature on 5 new drugs that entered clinical trials in the last 4 years.
drug resistant M. tuberculosis, HIV therapy, BACTEC growth assay, fluoroquinolone, PA-824
Sequella, Inc., 9610 Medical Center Drive, Suite 200, Rockville, MD 20850, USA.